Hyundai BioLand Co Ltd
KOSDAQ:052260
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
H
|
Hyundai BioLand Co Ltd
KOSDAQ:052260
|
134B KRW |
Loading...
|
|
| FR |
|
L'Oreal SA
PAR:OR
|
212.2B EUR |
Loading...
|
|
| UK |
|
Unilever PLC
LSE:ULVR
|
119B GBP |
Loading...
|
|
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.5T INR |
Loading...
|
|
| UK |
|
HALEON PLC
LSE:HLN
|
36.7B GBP |
Loading...
|
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
40.8B USD |
Loading...
|
|
| DE |
|
Beiersdorf AG
XETRA:BEI
|
23.9B EUR |
Loading...
|
|
| JP |
|
Kao Corp
TSE:4452
|
3T JPY |
Loading...
|
|
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.3T INR |
Loading...
|
|
| IN |
|
Dabur India Ltd
NSE:DABUR
|
906.4B INR |
Loading...
|
|
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
Hyundai BioLand Co Ltd
Glance View
HYUNDAI BIOLAND Co., Ltd. engages in the manufacture and sale of pharmaceutical and functional products. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2001-05-17. The firm operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Hyundai BioLand Co Ltd is 44.8%, which is above its 3-year median of 40.5%.
Over the last 3 years, Hyundai BioLand Co Ltd’s Gross Margin has increased from 35.5% to 44.8%. During this period, it reached a low of 35.5% on Aug 30, 2022 and a high of 44.8% on Oct 30, 2025.
